SCHEMBL31029162

SCHEMBL31029162

N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 5/20 0.59
NOD1 Q9Y239 9/20 0.58
GRM8 O00222 1/20 0.56
GRM6 O15303 1/20 0.56
GRIN2D O15399 1/20 0.56
GRIN3B O60391 1/20 0.56
GSR P00390 1/20 0.56
CYP1A2 P05177 1/20 0.56
GRIK1 P39086 1/20 0.56
GRM5 P41594 1/20 0.56
GRIA1 P42261 1/20 0.56
GRIA2 P42262 1/20 0.56
GRIA3 P42263 1/20 0.56
SLC1A3 P43003 1/20 0.56
SLC1A2 P43004 1/20 0.56
SLC1A1 P43005 1/20 0.56
GRIA4 P48058 1/20 0.56
GRIN1 Q05586 1/20 0.56
GRIN2A Q12879 1/20 0.56
GRIK2 Q13002 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31029187 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D
SCHEMBL31744910 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D
SCHEMBL31029217 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D
SCHEMBL31029180 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D
SCHEMBL31029185 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D
SCHEMBL31029201 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D
SCHEMBL31744923 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D
SCHEMBL31744942 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D
SCHEMBL31744879 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D
SCHEMBL31029202 1.00 FOLH1 (0.59) FOLH1NOD1GRM8GRM6GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382344-A1 Soluble GLP1/GIP/NPY2 Receptor Triple Agonists BOEHRINGER INGELHEIM INT GMH (DE) 2025-12-18 US claimed
US-20250382344-A1 Soluble GLP1/GIP/NPY2 Receptor Triple Agonists BOEHRINGER INGELHEIM INT GMH (DE) 2025-12-18 US disclosed
US-20240247080-A1 GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240247080-A1 GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS GLP1R, GIPR, NPY1R FOLH1 1020/4885NOD1 649/4885GRM8 613/4885
US-20250382344-A1 Soluble GLP1/GIP/NPY2 Receptor Triple Agonists GLP1R, GIPR, NPY1R FOLH1 479/4885NOD1 593/4885GRM8 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.